Similar Search Results

Cost-Effectiveness Analysis of Extended-Release Formulations of Oxybutynin and Tolterodine for the Management of Urge Incontinence

Hughes, Dyfrig A.; Dubois, Dominique - In: PharmacoEconomics 22 (2004) 16, pp. 1047-1059

Introduction: Oxybutynin and tolterodine are two drugs widely used for the management of overactive bladder and urge … cost effectiveness of oxybutynin extended-release (Oxy-XL), tolterodine extended-release (Tol-ER), tolterodine immediate …, their costs, compared with generic immediate-release (IR) oxybutynin, are significantly greater. This study compared the …

Persistent link: https://www.econbiz.de/10005449218

Corrigendum

Adis International Limited - In: PharmacoEconomics 30 (2012) 6, pp. 534-535

Persistent link: https://www.econbiz.de/10010548288

Management of Overactive Bladder: Defining the Role of Extended-Release Tolterodine

Keam, Susan J.; Perry, Caroline M. - In: Disease Management and Health Outcomes 12 (2004) 2, pp. 121-142

-release oxybutynin. The incidence of dry mouth with extended-release tolterodine or transdermal oxybutynin is similar. In economic models …-release tolterodine or immediate-release oxybutynin, and is as cost effective as extended-release oxybutynin. In conclusion, clinical and … efficacy and tolerability (including dry mouth) to transdermal oxybutynin. Extended-release tolterodine is, therefore, a …

Persistent link: https://www.econbiz.de/10005404696

Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease: A Review of the Evidence and Methodological Issues

Rutten-van Molken, Maureen P.M.H. Rutten-van Mlken; … - In: PharmacoEconomics 30 (2012) 4, pp. 271-302

Background:Background: Over 200 million people have chronic obstructive pulmonary disease (COPD) worldwide. The number of disease-year equivalents and deaths attributable to COPD are high. Guidelines for the pharmacological treatment of the disease recommend an individualized step-up approach in...

Persistent link: https://www.econbiz.de/10009653280

Economic Burden of Renal Cell Carcinoma: Part I - An Updated Review

Shih, Ya-Chen T.; Chien, Chun-Ru; Xu, Ying; Pan, I-Wen; … - In: PharmacoEconomics 29 (2011) 4, pp. 315-329

The economic burden of renal cell carcinoma (RCC) came into sharp focus when the UK National Institute for Health and Clinical Excellence (NICE) denied coverage (later reversed) of sunitinib for metastatic RCC. In the first of two articles that provide updated reviews and analyses of the...

Persistent link: https://www.econbiz.de/10010614347

Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations

Nyman, John A.; Jalal, Hawre J. - In: PharmacoEconomics 29 (2011) 3, pp. 173-174

Persistent link: https://www.econbiz.de/10010614369

Cost-Effectiveness Analysis in Markets with High Fixed Costs

Cutler, David M.; Ericson, Keith M. Marzilli. - In: PharmacoEconomics 28 (2010) 10, pp. 867-875

We consider how to conduct cost-effectiveness analysis when the social cost of a resource differs from the posted price. From the social perspective, the true cost of a medical intervention is the marginal cost of delivering another unit of a treatment, plus the social cost (deadweight loss) of...

Persistent link: https://www.econbiz.de/10008519890

The Effect of Cost Construction Based on Either DRG or ICD-9 Codes or Risk Group Stratification on the Resulting Cost-Effectiveness Ratios

Chumney, Elinor C.G.; Biddle, Andrea K.; Simpson, Kit N.; … - In: PharmacoEconomics 22 (2004) 18, pp. 1209-1216

Background: As cost-effectiveness analyses (CEAs) are increasingly used to inform policy decisions, there is a need for more information on how different cost determination methods affect cost estimates and the degree to which the resulting cost-effectiveness ratios (CERs) may be affected. The...

Persistent link: https://www.econbiz.de/10005590368

Acamprosate: Pharmacoeconomic Implications of Therapy

Foster, Rachel H.; McClellan, Karen J. - In: PharmacoEconomics 16 (1999) 6, pp. 743-755

_ Acamprosate is thought to reduce the craving for alcohol. The drug helps to maintain abstinence in alcohol-dependent patients who have successfully undergone detoxification. Abstinence rates during 3 to 12 months' treatment with acamprosate were approximately double those with placebo in most...

Persistent link: https://www.econbiz.de/10005590558

Economic Implications of Attention-Deficit Hyperactivity Disorder for Healthcare Systems

Leibson, Cynthia L.; Hall Long, Kirsten - In: PharmacoEconomics 21 (2003) 17, pp. 1239-1262

Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic conditions of childhood, with adverse consequences that persist through adolescence into adulthood. Thus, the burden of illness associated with ADHD is high for affected individuals, their families, and society at...

Persistent link: https://www.econbiz.de/10005448967

1
2
3
4
5
6
7
8
9
10
Next
Last